So They Say

People on the Private Side I set up the [National Cancer Institute’s biological response modification program beginning in 1980, and I left in February of 1984, and during that time I actually was trying to get more private involvement, to get a closer interface with the biotechnology industry, to get rotating scientists in from outside to try to open up and liberalize some of the viewpoints within the N.C.I. system.... They almost totally rejected it. It was a real closed shop in ter

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

People on the Private Side

I set up the [National Cancer Institute’s biological response modification program beginning in 1980, and I left in February of 1984, and during that time I actually was trying to get more private involvement, to get a closer interface with the biotechnology industry, to get rotating scientists in from outside to try to open up and liberalize some of the viewpoints within the N.C.I. system....

They almost totally rejected it. It was a real closed shop in terms of thought processes. Many of the people have been there all their lives. They’ve spent very little time at the university and virtually none in the private sector. So they’re very focused on what they do at the N.I.H. or N.C.I., and I think they have a little trouble seeing the forest for the trees. They’re very suspicious that things done outside have somehow got a prurient ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies